US Patent Issued to Maxymune Therapeutics on Sept. 30 for "Phenylalanine-based LAT1 inhibitors and uses thereof" (California Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,427,124, issued on Sept. 30, was assigned to Maxymune Therapeutics Inc. (Los Altos, Calif.).

"Phenylalanine-based LAT1 inhibitors and uses thereof" was invented by Bernd Jandeleit (Menlo Park, Calif.), Guangyao Gao (Los Altos, Calif.), Wolf-Nicolas Fischer (Sunnyvale, Calif.) and Gordon Ringold (Los Altos Hills, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Phenylalanine-based inhibitors of the Large Amino Acid Transporter 1 (LAT1) are disclosed. The compounds are useful in modulating the transcellular transport of substrates of LAT1 such as large neutral amino acids. The compounds are useful in immunomodulation therapies."

The patent was file...